Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 19

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Heritable pulmonary arterial hypertension+1

Recruiting

Study on Sotatercept for Improving Heart Function in Patients with Pulmonary Arterial Hypertension

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Sotatercept
  • Sponsor:Amsterdam UMC Stichting

Non-small cell lung cancer

Recruiting

Study on Cemiplimab and OSE2101 for Maintenance Therapy in Patients with ctDNA Positive Non-Small Cell Lung Cancer (NSCLC)

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Fondazione Ricerca Traslazionale

Asthma

Recruiting

Study on Tozorakimab for Adults with Uncontrolled Asthma Using Medium-to-High Dose Inhaled Corticosteroids

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:AstraZeneca AB

Abdominal infection+3

Recruiting

Study on High-Dose Short-Course Antibiotics for Critically Ill Patients with Pneumonia, Intra-Abdominal, or Bloodstream Infections: Ceftriaxone, Linezolid, and Cefotaxime

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cefotaxime
  • Sponsor:Universitair Ziekenhuis Gent

Alveolar proteinosis

Recruiting

Study on Inhaled Molgramostim for Children with Autoimmune Pulmonary Alveolar Proteinosis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Molgramostim
  • Sponsor:Savara ApS

Non-small cell lung cancer

Recruiting

Study on MaaT033 and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-1/PD-L1 Blockade Due to Antibiotic Use

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Institut Gustave Roussy

Non-small cell lung cancer+3

Recruiting

Study of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Budigalimab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Granulomatosis with polyangiitis

Recruiting

Study on Obinutuzumab for Patients with Relapsing Granulomatosis with Polyangiitis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Non-small cell lung cancer stage IV

Recruiting

Study on Osimertinib and Chemotherapy for Stage IV Non-Small Cell Lung Cancer with Atypical EGFR Mutations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Heidelberg University

Non-small cell lung cancer

Recruiting

Study on Treating Advanced Non-Small Cell Lung Cancer with Cemiplimab and Chemotherapy Based on Blood Tumor DNA Levels

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Fundacion GECP

Non-small cell lung cancer stage III

Recruiting

Study on Tislelizumab and Chemotherapy for Patients with Stage III PD-L1 Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Fondazione Ricerca Traslazionale

Asthma

Recruiting

Study on Stopping Dupilumab in Patients with Severe Asthma Who Have Been on the Drug for Over 3 Years

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.